Effectiveness of the bevacizumab‑irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second‑line treatments without this regimen

Ruiz-Sánchez,Daniel; Alaguero Calero,Miguel; Sastre-Heres,Alejandro   José; Iglesias García,María   Teresa; Calleja Hernandez,Miguel   Angel; Martínez Martinez,Fernando; Peña‑Díaz,Jaime

doi:10.3892/ol.2012.861

Effectiveness of the bevacizumab‑irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second‑line treatments without this regimen

Authors:
- Daniel Ruiz-Sánchez
- Miguel Alaguero Calero
- Alejandro José Sastre-Heres
- María Teresa Iglesias García
- Miguel Angel Calleja Hernandez
- Fernando Martínez Martinez
- Jaime Peña‑Díaz
View Affiliations

Affiliations: Hospital Pharmacy Department, Central University Hospital of Asturias, Oviedo, Asturias 33006, Spain, Hospital Pharmacy Department, Virgen de las Nieves Hospital, Granada 18014, Spain, Faculty of Pharmacy, University of Granada, Granada 18071, Spain
Published online on: August 14, 2012 https://doi.org/10.3892/ol.2012.861
Pages: 1114-1118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A retrospective cohort study was conducted to analyse the effectiveness of bevacizumab and irinotecan (BVZ/CPT‑11) as a second‑line treatment in patients with primary glioblastoma multiforme (GBM) in comparison with a control group that were not administered BVZ/CPT‑11 at the first recurrence. The difference in overall survival (OS) between the two groups was used as a predictor of effectiveness. OS was calculated according to prognostic factors and gender. A total of 28 and 32 patients were enrolled in the BVZ/CPT‑11 cohort and control group, respectively. The median OS was 17.94 months (95% CI, 14.91‑20.96) in the BVZ/CPT‑11 treatment cohort and 10.97 months (95% CI, 7.65‑14.30) in the control cohort. The results obtained on the effectiveness of BVZ/CPT‑11 treatment in patients with primary GBM are consistent with data from previous studies. No significant differences were identified in OS based on prognostic factors; therefore, the latter cannot be used to select patients who would incur the greatest benefits from BVZ/CPT‑11 treatment.

View Figures

View References

1.	DN LouisH OhgakiOD WiestlerWK CaveneeThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol11497109200710.1007/s00401-007-0243-417618441
2.	JG GurneyN Kadan-LottickBrain and other central nervous system tumors: rates, trends, and epidemiologyCurr Opin Oncol13160166201010.1097/00001622-200105000-0000511307058
3.	SS BremPJ BiermanH BremCentral nervous system cancersJ Natl Compr Canc Netw93524002011
4.	F Laigle-DonadeyJY DelattreGlioblastoma in the elderlyGeriatr Psychol Neuropsychiatr Vieil91011062011(In French)
5.	I BaldiA HuchetL BauchetH LoiseauEpidemiology of glioblastomaNeurochirurgie56433440201010.1016/j.neuchi.2010.07.01120869733
6.	L BauchetH Mathieu-DaudéP Fabbro-PeraySociété Française de Neurochirurgie (SFNC)Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC)Société Française de Neuropathologie (SFNP)Association des Neuro-Oncologues d'Expression Française (ANOCEF)Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004Neuro Oncol12725735201010.1093/neuonc/noq03020364023
7.	S DeorahCF LynchZA SibenallerTC RykenTrends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001Neurosurg Focus20E1201010.3171/foc.2006.20.4.E116709014
8.	HUCA tumour register. 2008 Annual Report. Hospital Universitario Central de Asturias and Instituto Universitario Oncológico, Principality of Asturias, 2008. ISSN 1138–8501. http://10.15.65.11/huca/web/contenidos/servicios/rt/rt2008/rt2008.pdf. Accesed January 21, 2012
9.	R StuppWP MasonMJ van den BentEuropean Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy GroupsNational Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolamide for glioblastomaN Engl J Med352987996200510.1056/NEJMoa04333015758009
10.	R StuppME HegiWP MasonEuropean Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology GroupsNational Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol104594662009
11.	M LacroixD Abi-SaidDR FourneyA multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJ Neurosurg95190198200110.3171/jns.2001.95.2.019011780887
12.	JF MineoA BordronM BaronciniPrognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patientsActa Neurochir (Wien)149245253200710.1007/s00701-006-1092-y17273889
13.	AA BrandesA TosoniE FranceschiM ReniG GattaC VechtGlioblastoma in adultsCrit Rev Oncol Hematol67139152200810.1016/j.critrevonc.2008.02.005
14.	M MaxwellSP NaberHJ WolfeET Hedley-WhyteT GalanopoulosJ Neville-GoldenHN AntoniadesExpression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progressionCancer Res511345135119911705174
15.	JA TakahasiM FukumotoK IgarashiY OdaH KikuchiM HatanakaCorrelation of Basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomasJ Neurosurg76792798199210.3171/jns.1992.76.5.07921564542
16.	J FolkmanTumor angiogenesis: Therapeutic implicationsN Engl J Med28511821186197110.1056/NEJM1971111828521084938153
17.	HS FriedmanMD PradosPY WenBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol2747334740200910.1200/JCO.2008.19.872119720927
18.	AD NordenGS YoungK SetayeshBevacizumab for recurrent malignant gliomas, efficacy, toxicity and patterns of recurrenceNeurology70779787200810.1212/01.wnl.0000304121.57857.3818316689
19.	TN KreislL KimK MoorePhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol27740745200910.1200/JCO.2008.16.305519114704
20.	JJ VredenburghA DesjardinsJE HerndonBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol2547224729200710.1200/JCO.2007.12.244017947719
21.	RM ZunigaR TorcuatorR JainEfficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol91329336200910.1007/s11060-008-9718-y18953493
22.	V Stark-VanceBevacizumab and CPT-11 in the treatment of relapsed malignant gliomaNeuro Oncol7Suppl369abstr 3422005
23.	S RavalS HwangL DorsettBevacizumab and irinotecan in patients with recurrent glioblastoma multiformeJ Clin Oncol25Supplabstr 20782007
24.	JJ VredenburghA DesjardinsJE Herndon IIPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res1312531259200710.1158/1078-0432.CCR-06-230917317837
25.	SA AliWM McHaylehA AhmadBevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 casesJ Neurosurg109268272200810.3171/JNS/2008/109/8/026818671639
26.	F BoksteinS ShpigelDT BlumenthalTreatment with bevacizumab and irinotecan for recurrent high-grade glial tumorsCancer11222672273200810.1002/cncr.2340118327820
27.	TF CloughesyMD PradosPY WenA phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment refractory glioblastoma (GBM)J Clin Oncol26Supplabstr 2010b2008
28.	A DesjardinsDA ReardonJE Herndon IIBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasClin Cancer Res1470687073200810.1158/1078-0432.CCR-08-026018981004
29.	S GuiuS TaillibertO ChinotBevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter StudyRev Neurol (Paris)1645885942008(In French)
30.	MR GilbertM WangK AldapeRTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)J Clin Oncol27Supplabstr 20112009
31.	PL NghiemphuW LiuY LeeBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology7212171222200910.1212/01.wnl.0000345668.03039.9019349600
32.	HS PoulsenK GrunnetM SorensenBevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursActa Oncol485258200910.1080/0284186080253792419031176
33.	T CloughesyJJ VredenburghB DayUpdated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN studyJ Clin Oncol28Supplabstr 20082010
34.	A DesjardinsJJ VredenburghDA ReardonLongterm survival from the initial trial of bevacizumab and irinotecanJ Clin Oncol28Supplabstr 20452010
35.	MH CohenYL ShenP KeeganR PazdurFDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiformeOncologist1411311138200910.1634/theoncologist.2009-012119897538
36.	M SeizU KraVtCF FreyschlagLong-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institutionJ Cancer Res Clin Oncol13616911695201010.1007/s00432-010-0827-620177703